New Data Show CeQur Simple Insulin Delivery Device Improves Glycemic Control Among People with Type 2 Diabetes

- Patients transitioned easily from multiple-daily insulin injections to PaQ®, which safely and effectively managed blood glucose -

HORW, Switzerland, Feb. 19, 2015 /PRNewswire/ -- CeQur® SA, a leader in simple insulin infusion for people with type 2 diabetes, today announced preliminary results from a new study demonstrating that the company's PaQ® Insulin Delivery Device improves glycemic control among people with type 2 diabetes. The data were presented at the 8th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Paris.

The single-arm, treat-to-target pilot study involved eight people with type 2 diabetes, all of whom transitioned from established regimens of multiple-daily insulin injections to the three-day, wearable PaQ device. After 12 weeks of PaQ use, preliminary results from six study participants showed an average reduction in HbA1c of 1.8 (+/-0.9 percent).

Total daily insulin dose and participants' weight at the end of the study were both similar to baseline. No severe hypoglycemic events or serious adverse events occurred during the study.

"Results from this study show that PaQ may free people from the burden of multiple-daily insulin injections and improve their glycemic control," said Julia Mader, MD, of Medical University of Graz, Austria, who presented the PaQ data in Paris. "It's very exciting, because it suggests we are rapidly moving toward a time when simple insulin delivery could help many people with type 2 diabetes manage their disease more comfortably and effectively."

Half of all patients requiring multiple-daily insulin injections report they intentionally skip doses because they consider the injections embarrassing, inconvenient, painful, and/or disruptive to their daily activities.[1] Continuous, subcutaneous insulin infusion (CSII) is an alternative to insulin injections, but adoption has been limited by the complexity and cost of existing, approved CSII devices.

Previous studies have demonstrated that the discreet PaQ device is both safe and easy to use, and is associated with high patient acceptance and satisfaction.

"The significant improvement in glycemic control that study participants experienced demonstrates that PaQ safely and effectively addresses many of the issues that make daily injection therapy a challenge for so many people with diabetes, and, importantly, can provide better clinical outcomes," said Douglas Lawrence, CEO of CeQur.

The Need for Simple Insulin Infusion

Every day more than 11 million people with type 2 diabetes in the United States and Europe inject insulin to manage their disease. The majority of these people are not achieving target glycemic control. Studies suggest that simple CSII regimens may improve glycemic control and quality of life among these individuals, however, current CSII has not been widely used in this population to date due to its complexity and cost.

About PaQ®

PaQ Insulin Delivery Device is a simple and cost effective three-day insulin delivery device that enables patients to experience the benefits of CSII without the complexity of daily insulin injections. PaQ provides three days of consistent, basal insulin along with easy, on-demand bolus insulin. PaQ can reduce known barriers to insulin therapy and has proven effective in clinical trials and usability studies. PaQ has CE Mark approval and will address the emerging $3 billion market for simple insulin infusion.

About CeQur® SA

CeQur is dedicated to developing and commercializing advanced insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of  their disease. The company is headquartered in Horw, Switzerland, with operations in Nordborg, Denmark and Marlborough, Massachusetts.

CeQur was established in January 2008.  The company's lead product candidate is the PaQ Insulin Delivery Device, a three-day, wearable device that provides freedom from multiple daily injections.  More information can be found at www.cequrcorp.com.

Media Contact:
Michele Parisi
Forward Health Communications, Inc.
925-429-1850

[1] Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care 2010;33:240-5

SOURCE CeQur SA



RELATED LINKS
http://www.cequrcorp.com

Did you like this article?